Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combination with bevacizumab in ten patients with metastat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F. Stephen Hodi, Mitchell Denker, Vincent Leveque, Marta Cañamero, Galina Babitski, Hartmut Koeppen, James Ziai, Neeraj Sharma, Fabien Gaire, Daniel S. Chen, Daniel Waterkamp, Priti S. Hegde, David F. McDermott
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2016
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/6805535216ff4aaca60ddedaf5252687
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6805535216ff4aaca60ddedaf5252687
record_format dspace
spelling oai:doaj.org-article:6805535216ff4aaca60ddedaf52526872021-12-02T17:31:35ZAtezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma10.1038/ncomms126242041-1723https://doaj.org/article/6805535216ff4aaca60ddedaf52526872016-08-01T00:00:00Zhttps://doi.org/10.1038/ncomms12624https://doaj.org/toc/2041-1723Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combination with bevacizumab in ten patients with metastatic renal cell carcinoma.Jeffrey J. WallinJohanna C. BendellRoel FunkeMario SznolKonstanty KorskiSuzanne JonesGenevive HernandezJames MierXian HeF. Stephen HodiMitchell DenkerVincent LevequeMarta CañameroGalina BabitskiHartmut KoeppenJames ZiaiNeeraj SharmaFabien GaireDaniel S. ChenDaniel WaterkampPriti S. HegdeDavid F. McDermottNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Jeffrey J. Wallin
Johanna C. Bendell
Roel Funke
Mario Sznol
Konstanty Korski
Suzanne Jones
Genevive Hernandez
James Mier
Xian He
F. Stephen Hodi
Mitchell Denker
Vincent Leveque
Marta Cañamero
Galina Babitski
Hartmut Koeppen
James Ziai
Neeraj Sharma
Fabien Gaire
Daniel S. Chen
Daniel Waterkamp
Priti S. Hegde
David F. McDermott
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
description Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combination with bevacizumab in ten patients with metastatic renal cell carcinoma.
format article
author Jeffrey J. Wallin
Johanna C. Bendell
Roel Funke
Mario Sznol
Konstanty Korski
Suzanne Jones
Genevive Hernandez
James Mier
Xian He
F. Stephen Hodi
Mitchell Denker
Vincent Leveque
Marta Cañamero
Galina Babitski
Hartmut Koeppen
James Ziai
Neeraj Sharma
Fabien Gaire
Daniel S. Chen
Daniel Waterkamp
Priti S. Hegde
David F. McDermott
author_facet Jeffrey J. Wallin
Johanna C. Bendell
Roel Funke
Mario Sznol
Konstanty Korski
Suzanne Jones
Genevive Hernandez
James Mier
Xian He
F. Stephen Hodi
Mitchell Denker
Vincent Leveque
Marta Cañamero
Galina Babitski
Hartmut Koeppen
James Ziai
Neeraj Sharma
Fabien Gaire
Daniel S. Chen
Daniel Waterkamp
Priti S. Hegde
David F. McDermott
author_sort Jeffrey J. Wallin
title Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
title_short Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
title_full Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
title_fullStr Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
title_full_unstemmed Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
title_sort atezolizumab in combination with bevacizumab enhances antigen-specific t-cell migration in metastatic renal cell carcinoma
publisher Nature Portfolio
publishDate 2016
url https://doaj.org/article/6805535216ff4aaca60ddedaf5252687
work_keys_str_mv AT jeffreyjwallin atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT johannacbendell atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT roelfunke atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT mariosznol atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT konstantykorski atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT suzannejones atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT genevivehernandez atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT jamesmier atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT xianhe atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT fstephenhodi atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT mitchelldenker atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT vincentleveque atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT martacanamero atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT galinababitski atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT hartmutkoeppen atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT jamesziai atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT neerajsharma atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT fabiengaire atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT danielschen atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT danielwaterkamp atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT pritishegde atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
AT davidfmcdermott atezolizumabincombinationwithbevacizumabenhancesantigenspecifictcellmigrationinmetastaticrenalcellcarcinoma
_version_ 1718380557250854912

Ejemplares similares